Selling a Dermatology Practice in 2026: Multiples, Named Buyers, and the Operator Playbook

If you own a dermatology practice in 2026 — whether that is a single-MD office, a multi-provider group with Mohs surgery, or a small regional dermatology platform — the M&A market is one of the most consolidated in healthcare. PE-backed dermatology MSOs (Schweiger, Forefront, Advanced Dermatology, Pinnacle, US Dermatology Partners, Epiphany, West Dermatology, Anne Arundel) have rolled up the sector at scale, and the PE sponsors directly (GTCR, Audax, ABRY, Harvest, Partners Group, Chicago Pacific Founders) write platform-and-tuck-in checks regularly. The combination of recurring patient visits (skin cancer screenings, chronic conditions, cosmetic patient loyalty), strong commercial payer mix, and high-margin Mohs surgery / pathology / cosmetic revenue makes dermatology one of the most durable healthcare-services rollup themes.

What the asset is worth depends on three things: (1) service-line mix and Mohs surgery / pathology revenue capture, (2) payer mix and commercial in-network contract status, and (3) provider productivity, EMR modernization, and bench depth past the owner-physician. This guide covers real multiples ranges by profile, the named buyers transacting, and the operator-level diligence buyers will run.

This guide is about full dermatology practices (medical / surgical / cosmetic dermatology). If you operate a cosmetic-only aesthetic clinic or MedSpa without medical dermatology, our separate guide at how to sell a MedSpa is the right starting point.

Named dermatology M&A transactions (2021-2025)

The transactions below are public or widely-disclosed deals. They show a deeply consolidated and well-capitalized buyer pool:

The named buyer landscape

National PE-backed dermatology MSOs (the primary buyer pool)

• Schweiger Dermatology Group (GTCR) — the largest US dermatology MSO with 400+ providers. Highly active tuck-in acquirer.
• Forefront Dermatology (Cassel Group + Partners Group) — 200+ providers across 20+ states.
• Advanced Dermatology and Cosmetic Surgery (Harvest Partners + ABRY Partners) — 150+ providers primarily FL/IL/NY/PA.
• U.S. Dermatology Partners (ABRY Partners) — multi-state platform primarily TX/AZ/CO. Active acquirer.
• Epiphany Dermatology (Audax Group) — multi-state, active tuck-in pace.

Regional PE-backed platforms

• Pinnacle Dermatology (Chicago Pacific Founders) — multi-state.
• Anne Arundel Dermatology (PE-backed) — Mid-Atlantic.
• West Dermatology (PE-backed) — West Coast.
• Riverchase Dermatology (PE-backed Florida).
• Dermatology Associates of Plymouth Meeting, Bay Area Dermatology, plus multiple regional platforms with PE backing.

PE sponsors active in this space

• GTCR — Schweiger; one of the most active healthcare-services PE sponsors.
• Audax Group — Epiphany Dermatology.
• ABRY Partners — U.S. Dermatology Partners + Advanced Dermatology (co-sponsor).
• Harvest Partners — Advanced Dermatology (co-sponsor).
• Cassel Group + Partners Group — Forefront.
• Chicago Pacific Founders — Pinnacle.
• Aldrich Capital, NaviMed Capital, Webster Equity Partners, Linden Capital, BlackRock-backed platforms — multiple other healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: integrated service-line mix (Mohs surgery + general derm + cosmetic + pathology), named commercial in-network status, modern EMR (Modernizing Medicine EMA is the operator standard), provider productivity (25-40 encounters/day/MD), pathology revenue capture (in-house lab or strategic-partner relationship), multi-MD platform with succession in place, audited financials, real management bench.
• Will compress or reject: owner-physician dependence, Medicare-heavy payer mix without commercial diversification, single-service-line concentration (cosmetic-only or Mohs-only), no pathology revenue capture, legacy EMR or paper charts, single-MD-only practices (limited succession), physician-retirement timing without bench, unaudited financials, anti-kickback / Stark issues on pathology arrangements.

The operator-level KPI playbook buyers will diligence

Service-line mix and revenue composition

• General dermatology %: Office-visit-based medical dermatology (acne, eczema, psoriasis, skin cancer screening). The volume backbone.
• Mohs surgery %: Premium high-margin service line; 15-30% Mohs revenue is the platform benchmark for the highest multiples.
• Cosmetic %: Injectables, laser, body contouring, skin care — cosmetic revenue mix adds patient loyalty and revenue diversification.
• Pathology %: In-house lab or strategic-partner pathology revenue. Pathology revenue capture is a major multiple-builder; structured Stark-compliantly.
• Average revenue per encounter: Track by service line; general derm typically $200-$400, Mohs $1,500-$3,500, cosmetic varies widely.

Payer mix and contracting

• Commercial percentage: 60%+ commercial is the platform benchmark.
• Medicare percentage: 25-35% Medicare is healthy; above 50% materially compresses.
• Medicaid: <15% Medicaid (dermatology is selective on Medicaid acceptance).
• In-network status: Anthem/Elevance, UHC, Aetna, Cigna, BCBS-by-state, plus regional payers.
• Single-payer concentration: No single payer above 25%.

Provider productivity

• Encounters per day per MD: 25-40 encounters/day is platform-benchmark; high-productivity practices can reach 45-55.
• RVU productivity: Track wRVU per provider per day.
• PA / NP scaling: PA/NP support extends MD productivity; documented scope-of-practice and supervision.
• Mohs surgeon utilization: Days per week dedicated to Mohs, cases per day, scheduling utilization.

EMR and operating system

• EMR: Modernizing Medicine EMA is the dermatology-specific operator standard (with built-in templates, workflow, image management). NextGen Healthcare, Athenahealth, Epic also common. Legacy or home-grown systems trigger discount.
• Practice management: Integrated PM + EMR + revenue cycle preferred.
• Image management: Dermoscopy, total-body photography, mole-mapping integration.
• Patient portal and engagement.

Pathology and accreditation

• In-house pathology lab: If you operate an in-house path lab, document CLIA certification, CAP accreditation (where applicable), and Stark-compliant structure.
• Strategic-partner pathology: If outsourced, document the partner relationship, fee structure, and Stark/anti-kickback compliance.
• Mohs surgeon credentials: Board-certified dermatologists with Mohs fellowship; ACMS membership; documented case volumes and outcomes.

Provider bench and succession

• Provider count and tenure: Number of MDs, PAs, NPs; tenure with the practice.
• Average MD age and retirement pipeline: Track succession risk explicitly.
• Provider compensation model: Documented physician compensation, productivity-based vs. base + bonus.
• Equity rollover / earnout structure expectations: Many PE-MSO deals include equity rollover for selling physicians; structure expectations early.

RCM

• Days in AR: <40 days is healthy.
• Denial rate: <8% first-pass.
• Bad-debt write-offs: <3% of billed revenue.
• Patient self-pay collection rate.

Dangers and traps in dermatology M&A

1. Stark and anti-kickback exposure on in-house pathology

In-office ancillary services exceptions to Stark are real but technical. Any in-house pathology arrangement needs explicit Stark-compliant structure (group practice exception, ancillary services exception, supervision and billing structure documented). Get health-care counsel review before going to market.

2. Single-MD-only practices and limited succession

If the practice is a single-MD operation, multiples compress because the buyer assumes 12-24 months of transition risk and the MD likely needs to stay through earnout. Single-MD practices with no PA/NP bench and no second MD on staff sell at the lower end of the range.

3. Owner-physician retirement timing

If the owner physician is close to retirement and there is no in-place successor MD, the practice value risk-adjusts down. Best outcomes occur when there is a 2-3 year transition runway with a successor in place.

4. Medicare-heavy payer mix

If Medicare exceeds 50% of revenue, premium multiples become difficult because commercial-payer mix is the platform-MSO benchmark. Skin-cancer-screening-heavy practices in retirement-community areas often face this.

5. Mohs surgeon dependence

If 35%+ of revenue runs through a single Mohs surgeon, that is a key-person risk. Document long-tenured employment, develop a second Mohs surgeon on staff, or structure earnout/equity rollover to retain.

6. Cosmetic concentration without medical anchor

Cosmetic-only practices have a different (lower-multiple) buyer pool than integrated medical + cosmetic dermatology. If you are cosmetic-focused, our MedSpa guide is the right starting point.

7. Legacy EMR and image-management integration discount

Modernizing Medicine EMA is the operator standard for dermatology. Legacy or home-grown systems trigger buyer-side integration project and discount.

8. Provider 1099 vs. W-2 classification

If providers (especially PAs/NPs) are 1099 contractors, that may raise classification questions in diligence. W-2 with documented HR is cleaner.

9. Real-estate ownership and rent-rate fairness

If the selling physician owns the real estate, expect post-close rent-rate negotiation. Get a market rent appraisal and document a fair-market-value lease structure.

10. Equity-rollover expectations vs. cash-at-close

Most PE-MSO dermatology deals include 20-40% equity rollover for the selling physicians. Understand the equity rollover dynamics, valuation of rollover equity, and second-sale terms before signing an LOI.

Our POV on dermatology M&A in 2026

The honest read on the market: dermatology is one of the most consolidated and well-capitalized healthcare-services M&A spaces. The PE-backed MSOs (Schweiger, Forefront, Advanced Dermatology, US Dermatology Partners, Epiphany, Pinnacle, Anne Arundel, West, Riverchase) have rolled up the sector at scale, and PE sponsors directly (GTCR, Audax, ABRY, Harvest, Partners Group, Chicago Pacific Founders) write platform-and-tuck-in checks regularly.

• If you are a single-site general dermatology practice ($500k-1.5M EBITDA), multiples are 5x-7x. Buyer pool is the PE-backed MSO platforms doing geographic tuck-ins.
• If you are a multi-MD single-site or 2-3 location practice ($1.5-4M EBITDA), you are in the tuck-in sweet spot. Multiples 6x-9x. A real competitive process matters.
• If you are a small regional group (3-10 providers), the buyer pool widens to include PE sponsors directly looking for sub-platforms. Multiples 7x-10x.
• If you are a mid-size platform (10-30 providers, $5-15M EBITDA), you are highly leveraged. PE-MSO acquirers + direct PE sponsors will pay 8x-11x in a real auction.
• If you are a premium scale platform ($15M+ EBITDA, multi-state, integrated Mohs + general derm + cosmetic + pathology, named commercial in-network, real management bench), you are a strategic target. 10x-14x+ achievable.

The right time to prepare is 12-18 months before going to market — structure Stark-compliant pathology arrangements, modernize EMR (Modernizing Medicine EMA), develop the provider bench (especially Mohs surgeon redundancy), diversify service-line mix, and get audited financials in place. Equity rollover expectations are real — understand the dynamics before signing an LOI.

Preparing your dermatology practice for sale: 12-18 months out

1. Get audited or reviewed financials. Multi-year, clean accrual, documented add-backs.
2. Structure Stark-compliant pathology arrangement. Whether in-house or strategic-partner, document the structure with health-care counsel.
3. Modernize the EMR. Migrate to Modernizing Medicine EMA, NextGen Healthcare, Athenahealth, or Epic if you are on legacy systems.
4. Build provider bench and succession. If single-MD, recruit a second physician. If owner-near-retirement, develop the succession runway 2-3 years out.
5. Develop Mohs surgeon redundancy. Don’t be single-Mohs-surgeon-dependent.
6. Diversify service-line mix. Integrated medical + Mohs + cosmetic + pathology = premium.
7. Confirm commercial in-network status. Top 5 commercial payers in your markets, named in-network.
8. Document provider productivity, RVU metrics, and compensation.
9. Document real-estate arrangements. Market-rate leases on physician-owned real estate.
10. Run a competitive process. Schweiger, Forefront, Advanced Dermatology, US Dermatology Partners, Epiphany, Pinnacle, Anne Arundel, West, Riverchase, plus PE sponsors directly (GTCR, Audax, ABRY, Harvest, Partners Group, Chicago Pacific Founders) — a real auction is worth 1-3 turns of EBITDA over single-bidder negotiation.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a dermatology practice in 2026?

Single-site general dermatology practices ($500k-1.5M EBITDA) typically sell at 5x-7x. Multi-MD single-site or 2-3 location practices go 6x-9x. Small regional groups (3-10 providers, $3-8M EBITDA) go 7x-10x. Mid-size platforms (10-30 providers, $5-15M EBITDA) go 8x-11x. Premium scale platforms ($15M+ EBITDA, multi-state, integrated Mohs + general derm + cosmetic + pathology, named commercial in-network contracts) reach 10x-14x+.

Who are the active buyers of dermatology practices right now?

National PE-backed MSOs: Schweiger Dermatology Group (GTCR, 400+ providers), Forefront Dermatology (Cassel Group + Partners Group, 200+ providers), Advanced Dermatology and Cosmetic Surgery (Harvest Partners + ABRY Partners, 150+ providers), U.S. Dermatology Partners (ABRY Partners), Epiphany Dermatology (Audax Group). Regional platforms: Pinnacle Dermatology (Chicago Pacific Founders), Anne Arundel Dermatology, West Dermatology, Riverchase Dermatology. PE sponsors directly: GTCR, Audax Group, ABRY Partners, Harvest Partners, Cassel Group, Partners Group, Chicago Pacific Founders, Aldrich Capital, NaviMed Capital.

What hurts a dermatology practice’s valuation most?

Owner-physician dependence with no successor in place, Medicare-heavy payer mix above 50%, single-service-line concentration (cosmetic-only or Mohs-only), no pathology revenue capture, Stark or anti-kickback exposure on pathology arrangements, legacy EMR or paper charts, single-MD-only practices without provider bench, Mohs-surgeon single-key-person risk, and undocumented add-backs.

How important is Mohs surgery in dermatology M&A?

Very important. Mohs surgery is the premium high-margin service line in dermatology. Practices with 15-30% Mohs revenue mix achieve significantly higher multiples than general-derm-only or cosmetic-only practices. Mohs surgeon redundancy (more than one Mohs surgeon on staff) is also a key risk mitigator.

What is the typical equity rollover in a dermatology MSO transaction?

Most PE-MSO dermatology deals include 20-40% equity rollover for the selling physicians. This means 20-40% of the deal value rolls into MSO platform equity (not cash at close). The rollover equity participates in the next platform exit (typically 4-7 years out), which can multiply value but also has risk. Understanding the rollover valuation, second-sale terms, and rollover equity rights is critical before signing an LOI.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

How long does it take to sell a dermatology practice?

Once you go to market with a buyer-paid advisor, a typical process runs 5-9 months from initial outreach to closing. Add 12-18 months of preparation work before going to market (financial cleanup, pathology structure, provider bench, EMR modernization).

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. That gives time to clean up financials, structure Stark-compliant pathology arrangements, modernize EMR, build provider and Mohs-surgeon redundancy, diversify service-line mix, and develop succession (especially if owner-near-retirement).

Related research

• How to sell a MedSpa (aesthetic-services-only)
• How to sell a dental practice
• How to sell a veterinary practice
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell an imaging center
• How to sell a clinical laboratory
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch